SRR934846
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 28.350854139290405
- age_years
- 42
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.735
- INTERFERON_GAMMA_RESPONSE+0.634
- E2F_TARGETS+0.578
- G2M_CHECKPOINT+0.542
- MYC_TARGETS_V2+0.497
- ANGIOGENESIS+0.418
- MITOTIC_SPINDLE+0.418
- MYC_TARGETS_V1+0.415
- DNA_REPAIR+0.397
- ALLOGRAFT_REJECTION+0.352
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.376
- KRAS_SIGNALING_DN-0.366
- SPERMATOGENESIS-0.238
- MYOGENESIS-0.227
- ESTROGEN_RESPONSE_LATE-0.191
- ESTROGEN_RESPONSE_EARLY-0.101
- HEME_METABOLISM-0.080
- BILE_ACID_METABOLISM-0.066
- XENOBIOTIC_METABOLISM-0.042
- KRAS_SIGNALING_UP-0.006
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934949 | — | — | 0.957 |
| 2 | SRR934861 | — | — | 0.952 |
| 3 | SRR934840 | — | — | 0.952 |
| 4 | 62966348-1C16-4A6D-AA82-707B3F759D5C | — | — | 0.952 |
| 5 | 31A652B1-3BEB-4D78-BCA0-4C153EBC41E8 | — | — | 0.950 |
| 6 | SRR934925 | — | — | 0.948 |
| 7 | D717EAB5-3C67-4EF0-99BF-3416278BE492 | — | — | 0.948 |
| 8 | D9385661-DBBA-4AF7-B7E6-857BF84CF7CD | — | — | 0.944 |
| 9 | SRR934961 | — | — | 0.944 |
| 10 | D494D692-9EC2-429A-A0FE-696D2A152D4A | — | — | 0.943 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.735 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.634 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.578 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.542 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.497 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.418 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.418 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.415 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.397 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.352 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.352 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.349 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.343 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.336 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.335 | Inavolisib | — uncovered |
| APOPTOSIS | 0.314 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.314 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.298 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.275 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.275 | Inavolisib | — uncovered |